NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

| More on:
A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.

Image source: The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have been outperforming this year and delivered very strong returns for shareholders.

Since the start of the year, the private health insurer's shares are up a sizeable 24%.

This compares very favourably to the benchmark ASX 200 index, which is up approximately 6.5% over the same period.

Can NIB shares keep rising?

Unfortunately, the team at Macquarie thinks that the run is coming to an end, particularly given that a new headwind is emerging for one of NIB's businesses.

That headwind is the Department of Health preparing to respond to an Issues Paper assessing the level of commissions paid to third party agents.

The Department of Health is looking at the Overseas Student Health Cover market and is testing three items. Of particular interest to Macquarie is a potential cap on payments to third-party agents for distributing insurance policies to students.

While Macquarie notes that commission caps could make larger university contracts more valuable to NIB, it suspects that it could pressure the business model for agents.

Commenting on this potential headwind, the broker said:

A ~12% commission cap could be an outcome (some arrangements are currently 30%-40%). While insurer margins could increase in the short term, sales driven businesses (not supported by ancillary offerings) could struggle. Notably, NHF relies on sales agents (particularly in India), which could be at risk, while being underweight university contracts. Additionally, as one of the few insurers offering a full product lifecycle, slower sales to Students would negatively impact NHF's higher-margin Workers' policyholders.

We estimate Students represented ~33% / ~20% of Revenue / UOP in NHF's IIHI division in FY24. This would equate to ~2.2% of Group UOP, before accounting for stranded costs and conversion into Workers policies.

Shares tipped to fall

The note reveals that Macquarie has reaffirmed its underperform rating and $5.55 price target on NIB's shares. Based on its current share price of $6.87, this implies potential downside of 19% for investors over the next 12 months.

And while a ~4% dividend yield is expected over the next 12 months, this only limits the total negative return to approximately 15%.

Commenting on its underperform rating, the broker said:

Underperform. With multiple sub-divisions now experiencing operational headwinds, we retain our cautious outlook.

In light of this, investors may want to keep their powder dry for the time being and wait for a better entry point or for its headwinds to clear and tailwinds to emerge.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »